Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance

Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.